Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sophie Glatt"'
Autor:
Elisabeth De Leeuw, Karel F. A. Van Damme, Jozefien Declercq, Cedric Bosteels, Bastiaan Maes, Simon J. Tavernier, Laurent Detalle, Trevor Smart, Sophie Glatt, Nincy Debeuf, Julie Deckers, Sahine Lameire, Stefaan J. Vandecasteele, Nikolaas De Neve, Ingel K. Demedts, Elke Govaerts, Christiane Knoop, Karolien Vanhove, Michel Moutschen, Wim Terryn, Pieter Depuydt, Eva Van Braeckel, Filomeen Haerynck, Tine C. J. Hendrickx, Vanessa Parrein, Marianna Lalla, Claire Brittain, Bart N. Lambrecht
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-11 (2022)
Abstract Background The efficacy and safety of complement inhibition in COVID-19 patients is unclear. Methods A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO
Externí odkaz:
https://doaj.org/article/d9849f76afef44ef98c3e2da010f83fc
Autor:
Christopher Sayed, Seth B Forman, Christos C. Zouboulis, Lucian Ionescu, Dominique Baeten, George Schmieder, Sophie Glatt, Seth D Seegobin, Jamie Weisman, Stevan Shaw, R. Rolleri, Gregor B.E. Jemec
Publikováno v:
JAMA dermatology, 157(11), 1279-1288. American Medical Association
JAMA Dermatol
JAMA Dermatol
Importance Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high burden for patients and limited existing therapeutic options. Objective To evaluate the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b4c1d0ed65479af00e672e072431b06
https://pure.amc.nl/en/publications/efficacy-and-safety-of-bimekizumab-in-moderate-to-severe-hidradenitis-suppurativa-a-phase-2-doubleblind-placebocontrolled-randomized-clinical-trial(3a0da2c2-2eb5-44a6-8d23-19510f4b019b).html
https://pure.amc.nl/en/publications/efficacy-and-safety-of-bimekizumab-in-moderate-to-severe-hidradenitis-suppurativa-a-phase-2-doubleblind-placebocontrolled-randomized-clinical-trial(3a0da2c2-2eb5-44a6-8d23-19510f4b019b).html
Autor:
H Edwards, Ash Maroof, A El Baghdady, Xuan Li, Lucian Ionescu, Sandra Garcet, C Mistry, Pavan Vajjah, B Dizier, James G. Krueger, Mark I L Watling, M Page, Ruth Oliver, Sophie Glatt, Dominique Baeten, Stevan Shaw
Publikováno v:
British journal of dermatology. Wiley-Blackwell
Background: Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, which is currently under investigation for treatment of moderate-to-severe plaque psoriasis. Maintenance dosing every 4 weeks is well est
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c26482ef1ae45a1fc65b42dc0b19857d
https://pure.amc.nl/en/publications/bimekizumab-for-the-treatment-of-moderatetosevere-plaque-psoriasis(2fbd1a03-ee73-4a58-af39-d52b4a5db98c).html
https://pure.amc.nl/en/publications/bimekizumab-for-the-treatment-of-moderatetosevere-plaque-psoriasis(2fbd1a03-ee73-4a58-af39-d52b4a5db98c).html
Autor:
Debashis Sarker, Udai Banerji, Sarah Patricia Blagden, Natalie Cook, T.R. Jeffry Evans, Elizabeth Ruth Plummer, Marina Braun, Ann Cleverly, Nieves Diaz, Paul Jones, Ivan Matthews, Sophie Glatt
Publikováno v:
Journal of Clinical Oncology. 40:TPS221-TPS221
TPS221 Background: Despite recent advances, effective treatment for GI cancers remains a significant unmet medical need. Gremlin-1 is secreted by the peri-tumoral stroma and down-regulates bone morphogenetic proteins (BMP) -2, -4, and -7 (members of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8931a6f673b816be3b6276a391e9616a
https://doi.org/10.1200/jco.2022.40.4_suppl.tps221
https://doi.org/10.1200/jco.2022.40.4_suppl.tps221
Autor:
Emir Mesic, Piet H. van der Graaf, James R. Gosset, Sonia Roberts, Diana Hijdra, Jolie Harris, Kevin Beaumont, Tamara J. van Steeg, Kristina Ulrich, Wendy J. Winchester, Ian Lightbown, Sophie Glatt, Tomomi Matsuura, Neil Attkins
Publikováno v:
European Journal of Pharmaceutical Sciences. 109:S161-S167
PF-05105679 is a moderately potent TRPM8 blocker which has been evaluated for the treatment of cold pain sensitivity. The TRPM8 channel is responsible for the sensation of cold environmental temperatures and has been implicated in regulation of core
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f36242812cebb2642d884c85d2259a
https://doi.org/10.1016/j.ejps.2017.06.009
https://doi.org/10.1016/j.ejps.2017.06.009
Autor:
Stevan Shaw, Sophie Glatt, Dominique Baeten, Foteini Strimenopoulou, Iain B. McInnes, Georg Schett, Robert Landewé, Mark I L Watling, Lucian Ionescu, Peter C. Taylor
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, 78(8), 1033-1040. BMJ Publishing Group
Annals of the rheumatic diseases, 78(8), 1033-1040. BMJ Publishing Group
ObjectiveEvaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) and inadequate respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c543268a73c0c31ab241918f48f10b53
https://doi.org/10.1136/annrheumdis-2018-214943
https://doi.org/10.1136/annrheumdis-2018-214943
Publikováno v:
Clinical Pharmacokinetics. 44:1295-1304
To develop a population pharmacokinetic model and to determine the covariates affecting the pharmacokinetics of onercept (recombinant human tumour necrosis factor [TNF] receptor-1) in healthy subjects.Onercept pharmacokinetics data were obtained from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab3fa535bb79399110504c25d4279ec9
https://doi.org/10.2165/00003088-200544120-00008
https://doi.org/10.2165/00003088-200544120-00008
Autor:
James R. Gosset, Wendy Petit, Nicola Clear, David S. Reynolds, Pierre-Philippe Saintot, Kelly Conlon, Sonia Roberts, Jennifer C. Gardiner, Paul Alan Glossop, Susie Collins, Kevin Beaumont, Michael Postlethwaite, Wendy J. Winchester, Michael John Palmer, Sophie Glatt, Tomomi Matsuura, Andrews Mark David, Katrina Gore
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 351(2)
The transient receptor potential (subfamily M, member 8; TRPM8) is a nonselective cation channel localized in primary sensory neurons, and is a candidate for cold thermosensing, mediation of cold pain, and bladder overactivity. Studies with TRPM8 kno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::693715f4444cf08f7159790a4bc0ea42
https://pubmed.ncbi.nlm.nih.gov/25125580
https://pubmed.ncbi.nlm.nih.gov/25125580
Autor:
Bruno Daubeuf, Walter Reith, Yann Dean, Romain Roger Ballet, Laura Cons, Eric Hatterer, Sophie Glatt, Marie Kosco-Vilbois, Fabien Dépis
Publikováno v:
mAbs, Vol. 5, No 4 (2013) pp. 555-64
Fc-modified anti-human CD3ε monoclonal antibodies (mAbs) are in clinical development for the treatment of autoimmune diseases. These next generation mAbs have completed clinical trials in patients with type-1 diabetes and inflammatory bowel disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a644fbe67bebfa836b2788eb731f7343
https://europepmc.org/articles/PMC3906309/
https://europepmc.org/articles/PMC3906309/
Autor:
Pavan Vajjah, Dominique Baeten, Sophie Glatt, Lucian Ionescu, Stevan Shaw, Foteini Strimenopoulou, Serghei Popa
Publikováno v:
Annals of the Rheumatic Diseases. 75:95.3-96
Background Bimekizumab (UCB4940) is a potent and selective monoclonal antibody inhibiting the activity of both IL-17A and IL-17F, which are key pro-inflammatory cytokines overexpressed in skin lesions of patients with psoriasis.1 Blocking both IL-17A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e80d033f60705b8e6843f7b4a982d0
https://doi.org/10.1136/annrheumdis-2016-eular.2952
https://doi.org/10.1136/annrheumdis-2016-eular.2952